(CIDRAP News) – The British biotechnology company Acambis announced yesterday that it has launched the first clinical trial of its vaccine for West Nile virus, called ChimeriVax-West Nile.
The phase 1 trial will involve 60 adult volunteers in Lenexa, Kan., the company said in a news release. The volunteers will receive one of three doses of the West Nile vaccine or a licensed yellow fever vaccine that is being used as a control.
(CIDRAP News) An initial human trial of a West Nile virus (WNV) vaccine has yielded promising results, officials said today.
In the double-blind, randomized trial, all but one of the people who received the vaccine developed antibodies to it, according to an Associated Press (AP) report quoting Dr. Thomas Monath, chief scientist at Acambis, the company that created the vaccine.
TORONTO (CIDRAP News) Ten years after H5N1 avian influenza first began to raise fears of a potential pandemic, the world has a stronger set of tools to contain that virus and similar threats, but also a fresh awareness of humanity's vulnerability to fast-spreading diseases, experts said yesterday at an international conference on flu.
(CIDRAP News) – A recent outbreak of the debilitating tropical disease known as chikungunya fever in northern Italy apparently marks the mosquito-borne infection's first foothold in Europe, according to European health authorities.
(CIDRAP News) A report from the National Research Council (NRC) calls for some changes in a US Army immunization program for lab researchers who work with dangerous pathogens, saying the vaccines need to be made more accessible to civilian scientists.